Prevalence of erectile dysfunction patients with diabetes mellitus and its association with body mass index and glycated hemoglobin in Africa: a systematic review and meta-analysis

Wondimeneh Shibabaw Shiferaw^{1*}, Tadesse Yirga Akalu², Yared Asmare Aynalem¹

Authors

Wondimeneh Shibabaw Shiferaw, BSc, MSc 1* *Corresponding author Lecturer of Nursing, Department of Nursing, College of Health Science, Debre Berhan University

Address: P.O. Box 445, Debre Berhan, Ethiopia

Email: wshibabaw2015@gmail.com

Tadesse Yirga Akalu, BSc, MSc²

Lecturer of Nursing, Department of Nursing, College of Health Science, Debre markos

University

Address: P.O. Box 269, Debre Markos, Ethiopia

Email: tadesseyirga680@gmail.com

Yared Asmare Aynalem, BSc, MSc ¹

Lecturer of Nursing, Department of Nursing, College of Health Science, Debre Berhan University

Address: P.O. Box 445, Debre Berhan, Ethiopia

Email: yaredasmare123@gmail.com

Abstract

Background: Mortality and morbidity in patients with diabetes mellitus (DM) is attributed to

both the micro-vascular and macro-vascular complications. Variation among primary studies was

seen on the prevalence of erectile dysfunction in Africa. Therefore, this study was aimed to

estimate the pooled prevalence of erectile dysfunction patients with diabetes mellitus and its

association with body mass index and glycated hemoglobin in Africa.

Methods: PubMed, Web of Science, Cochrane library, Scopus, Psyinfo, Africa online journal

and Google Scholar were searched. A funnel plot and Egger's regression test were used to see

publication bias. I-squared statistic was used to check heterogeneity of studies. DerSimonian and

Laird random-effects model was applied to estimate the pooled effect size. The subgroup and

Meta regression analysis were conducted by country, sample size, and year of publication.

Sensitivity analysis was deployed to see the effect of single study on the overall estimation.

STATA version 14 statistical software was used for meta-analysis.

Result: A total of 20 studies with 5,177 study participants were included to estimate the pooled

prevalence. The pooled prevalence of erectile dysfunction patients with diabetes mellitus was

61.62% (95% CI: 48.35-74.9). BMI ≥ 30 kg/m² (AOR = 1.26; 95% CI: 0.73 –2.16), and glycated

hemoglobin $\geq 7\%$ (AOR = 0.93; 95% CI: 0.5–5.9), were identified factors though not statistically

significant associated with erectile dysfunction.

Conclusions: The prevalence of erectile dysfunction in Africa remains high. Therefore, situation

based interventions and country context specific preventive strategies could be developed to

reduce the magnitude of erectile dysfunction among patients with diabetes mellitus.

Keywords: erectile dysfunction, impotence, sexual dysfunction, diabetes mellitus, Africa

2

Introduction

Diabetes is a major public health problem, increasingly affecting millions of people across the globe [1]. About 425 million peoples are suffering from diabetes mellitus (DM) globally in 2017; by 2045 this will rise to 629 million [2]. In Africa the prevalence of DM will continue to rise, thus imposing an extra burden on a health care system [3]. Mortality and morbidity in patients with DM is result from both the micro and macro-vascular complications. One common complication of diabetes mellitus is erectile dysfunction (ED) [4]. ED is one of the common yet an underestimated complication of diabetes mellitus [5]. Erectile dysfunction is the inability to achieve and maintain an erection sufficient to permit satisfactory sexual intercourse [6]. It may result from psychological, neurologic, hormonal, arterial impairment or from a combination of these factors [7].

The pathophysiology of ED in DM is related to multiple mechanisms including endothelial dysfunction, accumulation of advanced glycation end products, oxidative stress and neuropathy [5]. Diabetes mellitus promotes the onset of ED via vasculopathy from endothelial dysfunction and autonomic neuropathy [8]. In addition, diabetes may affect the cavernous nerve terminals and endothelial cells, resulting in a deficiency of neurotransmitters [9]. It is estimated that the global prevalence of ED should reach 322 million by 2025 [10]. In a study conducted on Ethiopian men with diabetes, 79% of patients never complained about ED [11].

Large differences have been reported on prevalence of erectile dysfunction in different studies. For instance, it has been reported that 49% England [12], 35.8% in Italy [13], 65.4% in Korean [14], 86.1 in Saudi [15], 31% in Kuwait [16], 38.9 % in India [17], 75.0% in Bénin [18], 77.1% south Africa [19], and 67.9% in Ghana [20]. The risk factors for ED are multifactorial and complex. Studies suggest that risk factors for erectile dysfunction in patients with diabetes mellitus included hypertension[16, 18, 19, 21, 22], heart disease [21], cigarette smoking [16, 19, 21-23], low education level[16], increasing body mass index [16, 17, 20], poor glycemic control [16, 18, 20, 24], age above or equal to 50 years [16-18, 20, 23, 25], increasing duration of diabetes [18, 25], presence of depressive symptom [17], high income [20] fat-rich diets[26], and other diabetic complications [27].

Patients with erectile dysfunction might suffer from poor quality of life[22, 28], anxiety when sexual ability declines[29], mutual mistrust, general unhappiness, and fear of losing support from partner [30]. It is known that the good control of the disease is associated with reduced complications[18]. According to literature evidence about one-third of men with erectile dysfunction has improvement in sexual function based on lifestyle interventions, such as diet, exercise and weight loss, cessation of smoking, counseling, and appropriate glycemic control through diet [31, 32]. Different primary studies in Africa showed the magnitude of erectile dysfunction. However, variation among those studies was seen. Therefore, this systematic review and meta-analysis was aimed, to estimate the pooled prevalence of erectile dysfunction patients with diabetes mellitus and its association with body mass index and glycated hemoglobin in Africa.

METHODS

Data sources and literature search strategy

Electronic databases such as PubMed, Google Scholar, Africa journal of online, Scopus, Web of science, Psyinfo and Cochrane library were searched by authors independently and systematically. In addition, a manual search of gray literature and other related articles were deployed to identify additional relevant research. Data from International Diabetic Federation (IDF) was searched and used. This search employed articles published from 1st January 1990 to 4th September/ 2019. The search was restricted to the full text, free article, study category of human and English language publications. Likewise, authors were communicated for full text through email. The search was conducted using the following terms and phrases: "erectile dysfunction", "sexual dysfunction", "impotence" "diabetes mellitus", and "Africa". Boolean operators like "AND" and "OR" were used to combine search terms. Particularly, to fit advanced PubMed database, the following search strategy was used ("erectile dysfunction" OR impotence OR "sexual dysfunction") AND ("diabetes mellitus") AND (Africa).

PECOS guide

Type of participants

This review was considered studies that included adult male patients aged 18 or above, and who have been diagnosed with a DM.

Type of exposure

Study participants who had BMI≥30kg/m² and glycated hemoglobin greater than 7%

Comparison

Study participants BMI 18.5 – 24.9 kg/m² and glycated hemoglobin less than 7%

Study Outcome

The outcome of this study was the prevalence of erectile dysfunction among men with diabetes mellitus

Types of studies design

The systematic review was included studies done using observational designs such as retrospective or prospective cohort studies, cross-sectional and case control, where erectile dysfunction among diabetic mellitus patients have been reported.

Eligibility criteria

Studies were included in the meta-analysis if they: (1) All observational studies, which reported the prevalence of erectile dysfunction;(2) articles published in peer reviewed journals and gray literature:(3) published in the English language from 1990 to 2019;and (4) studies conducted in Africa, which included male participants. Studies were excluded if: (1) studies which were not fully accessed; (2) studies with duplicated citation; (3) studies with poor quality score as per stated criteria; (4) articles in which fail to determine the outcomes (erectile dysfunction); and (5) studies included only females.

Selection and quality assessment

Two independent investigators were screened the title and abstract. Data were extracted using standardized data extraction format prepared in a Microsoft excel by three independent authors.

5

For each article, we extracted data regarding the name of author's, year of publication, study area, study design, sample size, data collection year, sampling technique, diagnostic criteria used for erectile dysfunction, reported prevalence with its 95% confidence interval and information regarding the associated factors. When some information was missing, first or corresponding authors of the article were communicated at least twice in a month to obtain the variables of interest. The quality of each included study was assessed using Newcastle-Ottawa scale [33]. Representativeness of the sample, response rate, measurement tool used, comparability of the subject, appropriateness of the statistical test used to analyze the data are some of the key criteria in Newcastle–Ottawa scale. Studies were included in the analysis if they scored ≥5 out of 10 points in three domains of ten modified NOS components for cross-sectional study[34]. Any disagreements at the time of data abstraction were resolved by discussion and consensus (Supplementary file 1).

Statistical analysis

To obtain the pooled effect size, a meta-analysis using random-effects DerSimonian and Laird model was performed [35, 36]. Heterogeneity across the included studies was checked using the chi-square based Q test and the I^2 statistics test with a value $\geq 75\%$ for the first and P < 0.05 indicating the presence of significant heterogeneity [36]. To investigate the sources of heterogeneity meta-regression and sub group analyses were performed. Potential publication bias was assessed by visual inspection of a funnel plot. In addition, Egger regression test was conducted and a $p \equiv 0.05$ was considered statistically significant for the presence of publication bias [37]. Sensitivity analysis was deployed to see the effect of single study on the overall effect estimation. The meta-analysis was performed using the STATA version 14 statistical software for windows [38].

Data synthesis and reporting

To estimate the overall prevalence of erectile dysfunction in patients with diabetes mellitus, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was used [39]. The entire process of study screening, selection and inclusion were described with the aid of a flow diagram. Results were presented using forest plots and summary tables (Supplementary file 2-PRISMA checklist).

Result

Search results


In the first step of our search, 1,622 studies were retrieved. About 1,617 studies were found from seven international databases and the remaining 5 were through manual search. Databases includes; PubMed (43), Scopus (28), Google scholar (800), web of science (317), Cochrane library (3), Psyinfo (19) and Africa online journal (407). Of these, 879 duplicate records were identified and removed. From the remaining 743 articles, 677 articles were excluded after reading of titles and abstracts based on the pre-defined eligible criteria. Finally, 66 full text articles were assessed for eligibility criteria. Based on the pre-defined criteria and quality assessment, only 20 articles were included for the final analysis (Fig. 1)

Figure 1.PRISMA flow chart of study selection

Baseline characteristic of the included studies

In the current meta-analysis, a total of 20 studies with 5,177 study participants were included to estimate the pooled prevalence of erectile dysfunction among DM patients. Concerning study design, majority (95%) of the studies are cross-sectional. The studies varied substantially in sample size ranged from 70 to 599. The highest prevalence (95%) of erectile dysfunction was reported in a study conducted in South Africa[40], whereas the lowest prevalence (15.5%) was reported in a study conducted in Zimbabwe[41]. Overall information regarding the prevalence was obtained from various countries in Africa. Three of the studies were from Nigeria [42-44], three from Ethiopia[11, 45, 46], two from Zimbabwe[41, 47], two from South Africa [40, 48], one each from Guinea[49], Benin[18], Morocco[50], Egypt[24], Senegal[51], Kenya [52], Ivory coast [53], Tanzania[54], Uganda[55], and Ghana[20].

Regarding the sampling technique employed, in eleven of the studies[11, 20, 24, 41, 43, 44, 47, 50, 52, 53, 55] were used consecutive sampling technique to select study participants. However, two studies [49, 54] did not report the sampling methods used. Concerning tools, ten studies [24, 43-47, 49, 52-54] were used international index of erectile function, two [40, 48] used the sexual health inventory for men, one study [20] used golombok rust inventory of sexual satisfaction and seven studies[11, 18, 41, 42, 50, 51, 55] did not report the tool used to estimate the prevalence of erectile dysfunction patients with DM. The quality score of each primary study,



First Author	Publication	Country	study design	samp	prevalence	Data	Data	Sampling	Quality
	Year			le	(95%CI)	collection	Collection	Technique	score
	1			size		year	Tool		(10)
Amanyam C etal [42]	2016	Nigeria	Cross- sectional	178	45.1(37.8,52.4)	NR	NR	systematic random	7
Balde N etal [49]	2006	Guinea	Cross- sectional	187	48(40.8,55.2)	NR	International Index of Erectile Function	NR	7
Djrolo, F.etal [18]	2014	Benin	cross- sectional	150	75(68,81.9)	NR	NR	Systematic random	6
El Achhab Y etal [50]	2008	Morocco	Cross- sectional	89	82(74,89.9)	NR	NR	Consecutive	7
El Saghier EO et al [24]	2015	Egypt	cross- sectional	70	85.7(77.5,93.9)	March 2014 to January 2015.	International Index of Erectile Function-5	Consecutive	7
Gueye S etal [51]	1998	Senegal	Cross- sectional	431	16(12.5,19.5)	NR	NR	simple random	8
Kemp T etal[40]	2015	South Africa	cross- sectional	150	95(91.5,98.5)	NR	The Sexual Health Inventory for Men	simple random	7
Likata GMU etal [52]	2012	Kenya	cross- sectional	350	68.8(63.9,73.6)	NR	International Index of Erectile Function	Consecutive	7
Lokrou A etal [53]	2011	Ivory coast	Cross- sectional	112	74.1(65.9,82.2)	NR	International index of erectile function	Consecutive	7
Mutagaywa RK etal [54]	2014	Tanzania	cross- sectional	312	55.1(49.5,60.6)	May to December 2011	International Index of Erectile Function	NR	7

Nambuya .A etal [55]	1996	Uganda	cross- sectional	252	22.2(17,27.3)	1 january 1993 to 10 august 1994	NR	Consecutive	8
Olarinoye J etal [43]	2006	Nigeria	Cross- sectional	77	74(64.2,83.8)	NR	International Index of Erectile Function	Consecutive	7
Owiredu WK et al [20]	2011	Ghana	cross- sectional	300	67.9(62.4,73.3)	November, 2010 to March, 2011.	Golombok Rust Inventory of Sexual Satisfaction	Consecutive	7
Pasipanodya Ian etal [47]	2018	Zimbabw e	cross- sectional	348	73.9(69.3,78.5)	23 October 2013 to 09 July 2014	International Index of Erectile Function	Consecutive	6
Saravoye T [41]	2016	Zimbabw e	Cross- sectional	284	15.5(11.3,19.7)	NR	NR	consecutive	7
Seid A et al.[45]	2017	Ethiopia	cross- sectional	249	69.9(64.2,75.6)	January 1 – February 30, 2016	International Index of Erectile Function	systematic random	8
Seyoum B [11]	1998	Ethiopia	Cross- sectional	292	48.7(42.9,54.4)	NR	NR	Consecutive	6
Ugwumba FO etal [44]	2018	Nigeria	Cross- sectional	325	94.7(92.2,97.1)	September 2016 to December 2017	International Index of Erectile Function	Consecutive	7
Walle B	2018	Ethiopia	Cross- sectional	422	85.5(82.1,88.8)	January to March, 2016	international index of erectile function	systematic	6
Webb EM etal [48]	2014	South Africa	cluster randomize control trial	599	36(32.1,39.8)	NR	sexual health inventory for men	Systematic	8

Prevalence of erectile dysfunction

The finding of the current meta-analysis using random effects model showed that the estimated overall prevalence of erectile dysfunction patients with diabetes mellitus was 61.62% (95% CI: 48.35, 74.90) with high significant level of heterogeneity ($I^2 = 83.4\%$; p<0.001) (Fig. 2).




Figure 2. Forest plot of the prevalence of erectile dysfunction

Subgroup analysis

To overcome the presence of heterogeneity, subgroup analysis using country, publication year, sample size, and sampling technique was done. Based on this, the prevalence of erectile dysfunction found to be 71.37% in Nigeria, 67.29% in publication year above 2010, and 62.24% sample size greater or equal to three hundred (Table 2).

Table 2. The prevalence of erectile dysfunction and heterogeneity estimate with a p-value for the subgroup analysis

Sub-group		No of	study	Sample	Prevalence (95%CI)	p-value	I^2
		included		size			
By year of	Before 2010	6		1,337	48.25(27.76, 68.73)	< 0.001	81.2
publication	2010 and	14		3,849	67.29(53.48, 81.11)	< 0.001	86.6
	above						
Sample size	le size <300		12		61.21(43.35, 79.06)	< 0.001	82.8
	≥300			3,087	62.24(40.77, 83.70)	< 0.001	85.3
Country	y Nigeria		3		71.37(38.32,104.42)	< 0.001	86.8
	South Africa	2		749	65.51(7.9,123.32)	< 0.001	83.7
	Ethiopia	3		963	68.12(46.28,89.97)	< 0.001	86.4
	Zimbabwe	2		632	44.69(-12.54,101.12)	< 0.001	82.7
	Others	10		2,241	59.37(42.19,76.56)	< 0.001	78.4
Sampling	Systematic	5		1,598	74.11(57.58, 90.65)	< 0.001	72.7
technique	Simple random	2		501	50.74(-17.56,119.05)	< 0.001	89.3
	Consecutive	11		2,779	59.45(43.54,75.35)	< 0.001	85.2
	Not specified		2		60.97(35.40, 86.55)	< 0.001	76.1

Meta-regression analysis

To identify source of heterogeneity meta-regression was undertaken by considering year of publication, sample size and sampling technique. However, the result of meta regression showed that both covariates were not statistically significant for the presence of heterogeneity (Table 3).

Table 3. Meta-regression analysis for the included studies to identify source of heterogeneity

Variables	riables Category		Std.	t	P> t	[95%Conf.
			Err.			Interval]
By year of	Before 2010(reference)					
publication 2010 and above		14.138	13.217	1.07	0.304	(-14.41,42.69)
Sample size	<300 (reference)					
	≥300	2.249	12.312	0.18	0.858	(-24.35,28.84)
Sampling	Systematic	-2.648	22.565	-0.12	0.908	(-51.39,46.10)
technique	Simple random	-26.099	26.307	-0.99	0.339	(-82.93,30.73)
	Consecutive		19.319	-0.50	0.623	(-51.47,32.00)
	Not specified (reference)					

Sensitivity analysis

To evaluate the effect of individual study on the pooled effect size sensitivity analysis was conducted. The finding of sensitivity analyses using random effects model revealed that no single study influences the overall prevalence of erectile dysfunction (fig. 3).




Figure 3. Result of sensitivity analysis of the 20 studies

Publication bias

A funnel plot showed a symmetrical distribution (Fig. 4). Likewise, Egger's regression test (p=0.406) which indicated the absence of publication bias.




Figure 4. Funnel plot the presence of publication bias among 20 included studies

Body mass index

The pooled effects of five studies showed that body mass index $\geq 30 \text{kg/m}^2$ was not statistically associated with erectile dysfunction (Fig. 5). The heterogeneity test ($I^2 = 89.5\%$) shows significant evidence of variation across studies. The evidence from Egger's test shows that there was a no publication bias (P = 0.807).




Figure 5. The pooled effects of overweight on erectile dysfunction

Glycosylated hemoglobin (Hga1c)

According to the recent meta-analysis, those who had normal glycated hemoglobin were 7% less likely to develop erectile dysfunction compared to those who had glycated hemoglobin value \geq 7% although not statistically significant (OR: 0.93 (95% CI (0.15, 5.91)) (Fig. 6). The heterogeneity test (I^2 = 94.4%) showed a significant evidence of variation across studies. The result of Egger's test showed that no evidence of publication bias (P = 0.147).




Figure 6. The pooled effects of glycated hemoglobin ≥7% on erectile dysfunction

Discussion

The prevalence of erectile dysfunction in this meta-analysis estimated 61.62 % in patients with diabetes mellitus. This implies that there is a high magnitude of erectile dysfunction among diabetic patients, which shows inadequate control of diabetes mellitus related complication. Hence, serious and multifactorial approach is required to manage the diabetic related complications, which emphasis on the treatment adherence, screening for complication, encourage on self-care practice, and health information dissemination.

In comparison with other similar studies, this estimated prevalence of erectile dysfunction in Africa seems significant higher than report from a systematic review and meta-analysis conducted at global level that implies the prevalence of erectile dysfunction among diabetic patients was 52.5% [56]. This variation could be justified by the different diagnostic criteria of erectile dysfunction, the age of the participants in each study, duration and severity of diabetes in their participants.

The subgroup analysis of this study showed that the pooled prevalence of erectile dysfunction among diabetic patients in Nigeria was 71.37% (95% CI: 38.3, 104.4) which is higher than the prevalence in Ethiopia 68.12% (95% CI: 46.3, 89.9), South Africa 65.5% (95% CI; 7.9, 123.3), and Zimbabwe 44.69% (95% CI: 12.5, 101.1). This variation might be due to difference in health seeking behavior between the populations, differences in the diagnostic methods and sociodemographic characteristics.

Though we have identified two factors (body mass index and glycated hemoglobin), to conduct the pooled analysis of two or more AOR of studies, BMI \geq 30 kg/m² and glycated hemoglobin \geq 7% were not associated with erectile dysfunction among diabetic patients. Those who had BMI \geq 30 kg/m² were 26% more likely to develop erectile dysfunction. Thought it is not statistically significant. This finding supported by other studies conducted in Vietnam [57] and Brazil [58]. Those who had glycosylated hemoglobin < 7% were 7% less likely to develop erectile dysfunction. Thought it is not statistically significant. However, this finding supported by other studies conducted in Korean[14] and china [59].

This study has an implication for clinical practice and patients. Estimating the overall prevalence

of erectile dysfunction provide current evidence to design preventive measure ,to improve patient

quality of life, early detection of poorly controlled diabetic mellitus, close monitoring of poor

patient progress and management strategy for ED. In addition, identifying associated factors help

health care professional to consider during their clinical care.

Although this meta-analysis conducted with the use of comprehensive search strategy to

incorporate the studies there are some limitations that need to be considered in the future

research: First, It may be lacked representativeness because no data were found from the entire

continent; second, only English articles were considered; and third, this study do not identify all

the predictors of erectile dysfunction among patients with diabetes mellitus. Therefore, we would

like to recommend the conduct of further study using similar diagnostic tool to identify

associated factors for the development of erectile dysfunction among patient with diabetes

mellitus.

Conclusion and recommendations

This study revealed that the prevalence of erectile dysfunction was remains high in Africa.

Besides, the prevalence of erectile dysfunction differed by country. Therefore, situation based

interventions and country context specific preventive strategies could be developed to reduce the

magnitude of erectile dysfunction among patients with diabetes mellitus.

Abbreviations

AOR: Adjusted odd ratio; CI: Confidence Interval; DM: diabetes mellitus; ED: Erectile

Dysfunction; IDF: International Diabetic Federation; PRISMA: Preferred Reporting Items for

18

Systematic Reviews and Meta-Analyses.

Declaration

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The data analyzed during the current meta-analysis is available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.

Authors' contributions

WSS and TYA developed the protocol and involved in the design, selection of study, data extraction, and statistical analysis and developing the initial drafts of the manuscript. YAA and TYA involved in data extraction, quality assessment, statistical analysis and revising. WSS and YAA prepared the final draft of the manuscript. All authors read and approved the final draft of the manuscript.

Acknowledgements

Not applicable

Reference

- 1. Jain GC, Jangir RN: Modulation of diabetes-mellitus-induced male reproductive dysfunctions in experimental animal models with medicinal plants. *Pharmacognosy reviews* 2014, **8**(16):113.
- 2. IDF: **DIABETES ATLAS 8th edition** 2017.
- 3. Mbanya J-C, Sobngwi E: **Diabetes microvascular and macrovascular disease in Africa**. *Journal of cardiovascular risk* 2003, **10**(2):97-102.
- 4. Melman A, Gingell JC: **The epidemiology and pathophysiology of erectile dysfunction**. *The Journal of urology* 1999, **161**(1):5-11.
- 5. Msc AMIM: Erectile Dysfunction in Diabetes: An Overview International Journal of Innovative Studies in Medical Sciences 2019, **3**(1):13-14.

- 6. Consensus N: **Development Panel on Impotence. NIH Consensus Conference. Impotence.** *Jama* 1993, **270**:83-90.
- 7. Lue TF: **Erectile dysfunction**. New England journal of medicine 2000, **342**(24):1802-1813.
- 8. Heaton JP, Adams MA: Causes of erectile dysfunction. *Endocrine* 2004, **23**(2-3):119-123.
- 9. de Tejada IS, Goldstein I, Azadzoi K, Krane RJ, Cohen RA: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. New England journal of medicine 1989, 320(16):1025-1030.
- 10. Ayta I, McKinlay J, Krane R: **The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences**. *BJU international* 1999, **84**(1):50-56.
- 11. Seyoum B: **Impotence in Ethiopian diabetic men**. *East African medical journal* 1998, **75**(4):208-210.
- 12. Kolodny RC, Kahn CB, Goldstein HH, Barnett DM: **Sexual dysfunction in diabetic men**. *Diabetes* 1974, **23**(4):306-309.
- 13. Fedele D, Coscelli C, Santeusanio F, Bortolotti A, Chatenoud L, Colli E, Landoni M, Parazzini F: Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. *Diabetes care* 1998, **21**(11):1973-1977.
- 14. Cho N, Ahn C, Park J, Ahn T, Lee H, Park T, Kim I, Pomerantz K, Park C, Kimm K: Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. *Diabetic Medicine* 2006, **23**(2):198-203.
- 15. El-Sakka AI, Tayeb KA: **Erectile dysfunction risk factors in noninsulin dependent diabetic Saudi patients**. *The Journal of urology* 2003, **169**(3):1043-1047.
- 16. Al-Hunayan A, Al-Mutar M, Kehinde EO, Thalib L, Al-Ghorory M: **The prevalence** and predictors of erectile dysfunction in men with newly diagnosed with type 2 diabetes mellitus. *BJU international* 2007, **99**(1):130-134.
- 17. Dan A, Chakraborty K, Mondal M, Neogi R, Chatterjee S, Makhal M: Erectile dysfunction in patients with diabetes mellitus: Its magnitude, predictors and their bio-psycho-social interaction: A study from a developing country. *Asian journal of psychiatry* 2014, 7:58-65.
- 18. Djrolo F, Paraïso NM, Diarra O, Makoutode M: **Diabetes complications and associated factors in type 2 diabetic patients in Cotonou**. *Journal of Diabetes Mellitus* 2014, **4**(04):311.
- 19. De Klerk H, De Villiers P, Isaacs S: **Prevalence and characteristics of erectile dysfunction in black and mixed race primary care populations of the Cape Flats and Helderberg Basin area of the Western Cape, South Africa**. *South African Family Practice* 2003, **45**(1):14-20.
- 20. Owiredu WK, Amidu N, Alidu H, Sarpong C, Gyasi-Sarpong CK: **Determinants of sexual dysfunction among clinically diagnosed diabetic patients**. *Reproductive Biology and Endocrinology* 2011, **9**(1):70.
- 21. Berrada S, Kadri N, Mechakra-Tahiri S, Nejjari C: **Prevalence of erectile dysfunction and its correlates: a population-based study in Morocco**. *International journal of impotence research* 2003, **15**(S1):S3.

- 22. Seyam R, Albakry A, Ghobish A, Arif H, Dandash K, Rashwan H: **Prevalence of erectile dysfunction and its correlates in Egypt: a community-based study**. *International journal of impotence research* 2003, **15**(4):237.
- 23. Bortolotti A, Fedele D, Chatenoud L, Colli E, Coscelli C, Landoni M, Lavezzari M, Santeusanio F, Parazzini F: Cigarette smoking: a risk factor for erectile dysfunction in diabetics. *European urology* 2001, **40**(4):392-397.
- 24. El Saghier EO, Shebl SE, Fawzy OA, Eltayeb lM, Bekhet LM, Gharib A: **Androgen deficiency and erectile dysfunction in patients with type 2 diabetes**. *Clinical Medicine Insights: Endocrinology and Diabetes* 2015, **8**:CMED. S27700.
- 25. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB: **Association** of type and duration of diabetes with erectile dysfunction in a large cohort of men. *Diabetes care* 2002, **25**(8):1458-1463.
- 26. Kassier S, Veldman F: When science meets culture: the prevention and management of erectile dysfunction in the 21st century. South African Journal of Clinical Nutrition 2014, 27(1):7-12.
- 27. Malavige LS, Levy JC: **Erectile dysfunction in diabetes mellitus**. *The journal of sexual medicine* 2009, **6**(5):1232-1247.
- 28. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Rossi MC, Sacco M, Tognoni G: Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. *Diabetes care* 2005, **28**(11):2637-2643.
- 29. Chye PLH: **Traditional Asian folklore medicines in sexual health**. *Indian Journal of Urology* 2006, **22**(3):241.
- 30. Cooper S, Leon N, Namadingo H, Bobrow K, Farmer AJ: "My wife's mistrust. That's the saddest part of being a diabetic": A qualitative study of sexual well-being in men with Type 2 diabetes in sub-Saharan Africa. *PloS one* 2018, **13**(9):e0202413.
- 31. McVARY KT, Carrier S, Wessells H: **Smoking and erectile dysfunction: evidence based analysis**. *The Journal of urology* 2001, **166**(5):1624-1632.
- 32. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D: Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. *Jama* 2004, **291**(24):2978-2984.
- 33. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, Perruolo E, Parati G, Settings EWGoCRiLR: **Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis**. *PloS one* 2016, **11**(1):e0147601.
- 34. Yazew KG, Walle TA, Azagew AW: **Prevalence of anti-diabetic medication** adherence and determinant factors in Ethiopia: A Systemic Review and Meta-Analysis, 2019. *International Journal of Africa Nursing Sciences* 2019:100167.
- 35. DerSimonian R, Laird N: **Meta-analysis in clinical trials**. *Controlled clinical trials* 1986, **7**(3):177-188.
- 36. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J: **Assessing** heterogeneity in meta-analysis: Q statistic or I² index? *Psychological methods* 2006, 11(2):193.
- 37. Egger M, Davey-Smith G, Altman D: **Systematic reviews in health care: meta-analysis in context**: John Wiley & Sons; 2008.
- 38. StataCorp L: **Stata statistical software (version release 14)**. College Station, TX: Author 2015.

- 39. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: **The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration**. *PLoS medicine* 2009, **6**(7):e1000100.
- 40. Kemp T, Rheeder P: **The prevalence and associations of erectile dysfunction in a South African male diabetic urban population**. *Journal of Endocrinology, Metabolism and Diabetes of South Africa* 2015, **20**(3):134-139.
- 41. Saravoye T: **Prevalence and risk factors for diabetes chronic complications in Harare, Zimbabwe**. 2016.
- 42. Amanyam C, Yohanna S, Obilom R: **Assessment of sexual dysfunction in patients** with diabetes mellitus in the general outpatient clinic of Dalhatu Araf Specialist **Hospital Lafia**. *Nigerian Journal of Family Practice* 2016, **7**(3):35-42.
- 43. Olarinoye J, Kuranga S, Katibi I, Adediran O, Jimoh A, Sanya E: **Prevalence and determinants of erectile dysfunction among people with type 2 diabetes in Ilorin, Nigeria**. *The Nigerian postgraduate medical journal* 2006, **13**(4):291-296.
- 44. Ugwumba FO, Okafor CI, Nnabugwu II, Udeh EI, Echetabu KN, Okoh AD, Okorie JC: Prevalence of, and risk factors for erectile dysfunction in male type 2 diabetic outpatient attendees in Enugu, South East Nigeria. *Annals of African medicine* 2018, 17(4):215.
- 45. Seid A, Gerensea H, Tarko S, Zenebe Y, Mezemir R: **Prevalence and determinants of erectile dysfunction among diabetic patients attending in hospitals of central and northwestern zone of Tigray, northern Ethiopia: a cross-sectional study**. *BMC endocrine disorders* 2017, **17**(1):16.
- 46. Walle B, Lebeta KR, Fita YD, Abdissa HG: Prevalence of erectile dysfunction and associated factors among diabetic men attending the diabetic clinic at Felege Hiwot Referral Hospital, Bahir Dar, North West Ethiopia, 2016. BMC research notes 2018, 11(1):130.
- 47. Pasipanodya Ian Machingura VC: Erectile Dysfunction among Diabetic Patients at Parirenyatwa Group of Hospitals in Zimbabwe Texila International Journal of Public Health 2018, 6(2).
- 48. Webb EM, Rheeder P, Van Zyl DG: **Diabetes care and complications in primary care in the Tshwane district of South Africa**. *Primary care diabetes* 2015, **9**(2):147-154.
- 49. Balde N, Diallo A, Balde M, Kake A, Diallo M, Diallo M, Maugendre D: Erectile dysfunction and diabetes in Conakry (Guinea): frequency and clinical characteristics from 187 diabetic patients. In: *Annales d'endocrinologie: 2006*; 2006: 338-342.
- 50. El Achhab Y, Berraho M, Benslimane A, Chrit M, El Hassani H, Lyoussi B, Nejjari C: **Diabetes and erectile dysfunction in Morocco: epidemiological study among outpatients**. *EMHJ-Eastern Mediterranean Health Journal*, *14* (5), *1090-1100*, *2008* 2008.
- 51. Gueye S, Diop S, Ba M, Dagadou E, Fall P, Sow M, Mensah A: **Erectile dysfunction in diabetics. Epidemiological profile in Senegal**. *Progres en urologie: journal de l'Association française d'urologie et de la Societe française d'urologie* 1998, **8**(3):377-381.

- 52. Likata GMU, Kuria MW, Olando Y, Owiti FR: **Sexual dysfunction among patients** with diabetes mellitus. *Green J Med Sci* 2012, **2**:138-145.
- 53. Lokrou A, Soumahoro S: **Erectile dysfunction in patients with diabetes in Ivory Coast**. *MEDECINE DES MALADIES METABOLIQUES* 2011, **5**(2):203-207.
- 54. Mutagaywa RK, Lutale J, Aboud M, Kamala BA: **Prevalence of erectile dysfunction and associated factors among diabetic men attending diabetic clinic at Muhimbili National Hospital in Dar-es-Salaam, Tanzania**. *The Pan African Medical Journal* 2014, **17**.
- 55. Nambuya A, Otim M, Whitehead H, Mulvany D, Kennedy R, Hadden D: **The presentation of newly-diagnosed diabetic patients in Uganda**. *QJM: An International Journal of Medicine* 1996, **89**(9):705-712.
- 56. Kouidrat Y, Pizzol D, Cosco T, Thompson T, Carnaghi M, Bertoldo A, Solmi M, Stubbs B, Veronese N: **High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies**. *Diabetic Medicine* 2017, **34**(9):1185-1192.
- 57. Vo KT, Huynh HQ, Tran NQ, Goto A, Suzuki Y, Nguyen KT: **Prevalence of erectile dysfunction and its associated factors among Vietnamese men with type 2 diabetes**. *Journal of the ASEAN Federation of Endocrine Societies* 2014, **29**(1):19.
- 58. Moreira Júnior ED, Bestane WJ, Bartolo EB, Fittipaldi JAS: **Prevalence and determinants of erectile dysfunction in Santos, southeastern Brazil**. *Sao Paulo Medical Journal* 2002, **120**(2):49-54.
- 59. Yang G, Pan C, Lu J: **Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus**. *International journal of impotence research* 2010, **22**(5):310.




Figure 1. PRISMA flow chart of study selection